Regeneron wins injunction blocking Mylan from launching generic version of its eye drug Eylea (update)
Update 3:10pm: Adds analyst comment. Regeneron (NASDAQ:REGN) won a permanent injunction that blocks drugmakers including, ...
BioSpace6d
Lacks Family Lawsuits Seek Share of Profits Stemming from HeLa Cells
A suit against Novartis and Vitaris by Henrietta Lacks’ estate hinges on questions about the morality and legality of using ...
pharmaphorum3d
Mylan settles narcolepsy drug pay-for-delay case
Mylan has paid $96.5 million to settle claims it delayed launching a generic of narcolepsy drug Provigil in exchange for a payment from the originator, Cephalon. Reuters reported the settlement ...
pharmaphorum4d
Mylan launches Advair generic at 70% discount in US
Mylan has launched its generic version of GlaxoSmithKline’s respiratory blockbuster, Advair, at a 70% discount compared with the original drug. Cheaper competition to off-patent Advair has been ...
Medscape10d
MS Drugmaker Fined €462.6 Million for Disparaging Rival
The patent office decision would allow Mylan immediately to return to the market across Europe ... enforcement in the ...
India Today on MSN1mon
Indian pharma firms sign deal to produce, sell generic HIV drug lenacapavir
Hetero and Mylan, a subsidiary of Viatris, ensures that, once approved, generic versions of the drug will be made available ...
Viatris Tops Analyst Estimates in Q3
Pharmaceutical company Viatris (VTRS 13.52%) reported third-quarter 2024 financial results on Thursday, Nov. 7, that topped ...